| Methods | ALLOCATION CONCEALMENT: unclear BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation | |
| Participants | DIAGNOSIS: DSM‐IV panic disorder with or without agoraphobia (% agoraphobic unspecified) AGE: between 18 and 65 SEX: unspecified HISTORY: unresponsive to initial 15 sessions of CBT (51% of the original sample) PSYCHIATRIC COMORBIDITY: 16% suffered from mood disorders, 16% from additional anxiety disorders, and 9% suffered from somatoform disorders. MEDICAL COMORBIDITY: ‐ | |
| Interventions | ACUTE PHASE: 8 weeks 1. paroxetine (40 mg/d) + CBT (4 sessions over 8 weeks) 2. placebo + CBT ACUTE PHASE CO‐INTERVENTION: Patients who had been using benzo were asked either to discontinue their medication under supervision or to adhere to a fixed daily dose throughout the study. MAINTENANCE: ‐ MODE OF DISCONTINUATION: ‐ FOLLOW‐UP: ‐ |
|
| Outcomes | RESPONSE: 30% improvement in panic frequency, ACQ and ADS REMISSION: panic‐free GLOBAL: ‐ PANIC ATTACK: ‐ AGORAPHOBIA: MI, (ACQ, BSQ, ADS) GENERAL ANXIETY: FQ‐general anxiety DEPRESSION: ‐ FUNCTIONING: ‐ | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.